2 weeks Ago By ABMN Staff
Danaher Co. ( NYSE:DHR – Free Report ) – Analysts at Zacks Research cut their Q3 2024 earnings per share estimates for Danaher in a research note issued on Wednesday, August 28th. Zacks Research analyst R.
Department now forecasts that the conglomerate will post earnings of $1.55 per share for the quarter, down from their prior estimate of $1.56.
The consensus estimate for Danaher’s current full-year earnings is $7.59 per share. Zacks Research also issued estimates for Danaher’s Q3 2025 earnings at $1.
96 EPS and FY2026 earnings at $9.57 EPS. A number of other research analysts have also recently commented on DHR.
Leerink Partners boosted their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th.
TD Cowen boosted their price objective on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th.
Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target on the stock.
The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th.
Finally, Robert W. Baird boosted their price target on Danaher from $271.00 to $278.
00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.
94. Danaher Trading Up 0.4 % Shares of DHR opened at $267.
15 on Friday. The stock’s 50-day moving average is $259.39 and its two-hundred day moving average is $254.
86. The stock has a market cap of $197.87 billion, a PE ratio of 45.
28, a P/E/G ratio of 4.62 and a beta of 0.83.
Danaher has a 12 month low of $182.09 and a 12 month high of $281.70.
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.
04. Danaher ( NYSE:DHR – Get Free Report ) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.
72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15.
Danaher had a return on equity of 11.06% and a net margin of 16.94%.
The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion.
During the same quarter in the previous year, the business earned $2.05 earnings per share. The firm’s quarterly revenue was down 2.
9% compared to the same quarter last year. Insider Buying and Selling In related news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.
00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240.
The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link . In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.
00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.
37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.
44. The disclosure for this sale can be found here . Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last three months.
11.10% of the stock is currently owned by corporate insiders. Institutional Investors Weigh In On Danaher Institutional investors and hedge funds have recently modified their holdings of the stock.
Cary Street Partners Investment Advisory LLC lifted its position in shares of Danaher by 20.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after acquiring an additional 1,533 shares during the last quarter.
Caden Capital Partners LP lifted its position in shares of Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after acquiring an additional 15,313 shares during the last quarter.
Legacy Financial Advisors Inc. lifted its position in shares of Danaher by 2.4% during the 4th quarter.
Legacy Financial Advisors Inc. now owns 2,377 shares of the conglomerate’s stock valued at $550,000 after acquiring an additional 55 shares during the last quarter. JARISLOWSKY FRASER Ltd lifted its position in shares of Danaher by 10.
8% during the 4th quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after acquiring an additional 55,908 shares during the last quarter. Finally, HighPoint Advisor Group LLC acquired a new stake in shares of Danaher during the 4th quarter valued at $2,614,000.
Institutional investors and hedge funds own 79.05% of the company’s stock. About Danaher ( Get Free Report ) Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. Further Reading Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter .
.
